menu ☰
menu ˟

Stelara demonstrates safety, efficacy in highly refractory Crohn’s disease

25 Jun 2019
SAN DIEGO — Ustekinumab resulted in clinical remission of Crohn’s disease in more than half of patients in a large, highly refractory cohort, according to a study presented at Digestive Disease Week.“Ustekinumab (Stelara, Janssen) is a monoclon...

Click here to view the full article which appeared in Gastroenterology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.